Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KRAS mutant Erlotinib lung adenocarcinoma resistant detail...
KRAS G12X Gefitinib lung adenocarcinoma predicted - resistant detail...
KRAS mutant Salirasib lung adenocarcinoma no benefit detail...
MAP2K1 K57N Selumetinib lung adenocarcinoma sensitive detail...
KRAS mutant GI-4000 lung adenocarcinoma sensitive detail...
KRAS G12D Selumetinib lung adenocarcinoma decreased response detail...
KRAS G12D Selumetinib + BEZ235 lung adenocarcinoma sensitive detail...
KRAS G12D PX-866 lung adenocarcinoma sensitive detail...
KRAS G13X Gefitinib lung adenocarcinoma resistant detail...
FBXW7 R465H Temsirolimus lung adenocarcinoma sensitive detail...
FGFR3-TACC3 Ponatinib lung adenocarcinoma sensitive detail...
FGFR3-TACC3 BGJ398 lung adenocarcinoma sensitive detail...
KRAS G12D PD-0325901 lung adenocarcinoma sensitive detail...
ROS1 rearrange Crizotinib lung adenocarcinoma sensitive detail...
ERBB2 mutant Afatinib lung adenocarcinoma sensitive detail...
ALK rearrange ALK I1171T Alectinib lung adenocarcinoma resistant detail...
ALK rearrange ALK I1171T Crizotinib lung adenocarcinoma resistant detail...
Unknown unknown Nintedanib lung adenocarcinoma not applicable detail...
KRAS mutant AT13148 lung adenocarcinoma sensitive detail...
KRAS mut STK11 inact mut MLN0128 + Phenformin lung adenocarcinoma sensitive detail...
MAP2K1 Q56P Trametinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P Selumetinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P Refametinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P PD-0325901 lung adenocarcinoma sensitive detail...
MAP2K1 Y134C KRAS Q61H Trametinib lung adenocarcinoma no benefit detail...
MAP2K1 Y134C KRAS Q61H Refametinib lung adenocarcinoma no benefit detail...
BRAF mutant Trametinib lung adenocarcinoma sensitive detail...
KRAS mutant Trametinib lung adenocarcinoma sensitive detail...
NRAS mutant Trametinib lung adenocarcinoma resistant detail...
ABL1 R332W Imatinib lung adenocarcinoma sensitive detail...
ABL1 G321L Imatinib lung adenocarcinoma sensitive detail...
ABL1 R332W ABL1 T315I Imatinib lung adenocarcinoma resistant detail...
ABL1 R332W Dasatinib lung adenocarcinoma sensitive detail...
ABL1 G321L Dasatinib lung adenocarcinoma sensitive detail...
ABL1 R332W ABL1 T315I Dasatinib lung adenocarcinoma resistant detail...
IDH1 mutant Dasatinib lung adenocarcinoma resistant detail...
ERBB2 exon 20 ins Afatinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Afatinib lung adenocarcinoma conflicting detail...
ERBB2 G778_P780dup Afatinib lung adenocarcinoma predicted - sensitive detail...
KRAS G12C EZH2 pos DZNep + Selumetinib lung adenocarcinoma sensitive detail...
KRAS G12S EZH2 pos DZNep + Selumetinib lung adenocarcinoma sensitive detail...
KRAS G12D EZH2 pos DZNep + Selumetinib lung adenocarcinoma no benefit detail...
KRAS G12V EZH2 pos DZNep + Selumetinib lung adenocarcinoma no benefit detail...
KRAS G12C EZH2 pos GSK343 + Selumetinib lung adenocarcinoma sensitive detail...
KRAS G12C EZH2 pos Selumetinib + Tazemetostat lung adenocarcinoma sensitive detail...
KRAS G12D EZH2 pos GSK343 + Selumetinib lung adenocarcinoma no benefit detail...
KRAS G12D EZH2 pos Selumetinib + Tazemetostat lung adenocarcinoma no benefit detail...
KRAS G12D EZH2 pos DZNep + MK2206 lung adenocarcinoma sensitive detail...
KRAS G12D EZH2 pos GSK343 + MK2206 lung adenocarcinoma sensitive detail...
KRAS G12D EZH2 pos MK2206 + Tazemetostat lung adenocarcinoma sensitive detail...
KRAS G12V EZH2 pos DZNep + MK2206 lung adenocarcinoma no benefit detail...
KRAS G12C EZH2 pos DZNep + MK2206 lung adenocarcinoma no benefit detail...
KRAS G12S EZH2 pos DZNep + MK2206 lung adenocarcinoma sensitive detail...
KRAS G12C EZH2 pos GSK343 + MK2206 lung adenocarcinoma no benefit detail...
KRAS G12C EZH2 pos MK2206 + Tazemetostat lung adenocarcinoma no benefit detail...
KRAS G12V Binimetinib lung adenocarcinoma decreased response detail...
KRAS G12S Binimetinib lung adenocarcinoma decreased response detail...
KRAS G12C Binimetinib lung adenocarcinoma decreased response detail...
KRAS G12R Binimetinib lung adenocarcinoma decreased response detail...
KRAS G13C Binimetinib lung adenocarcinoma decreased response detail...
KRAS Q61K Binimetinib lung adenocarcinoma decreased response detail...
KRAS Q61H Binimetinib lung adenocarcinoma decreased response detail...
KRAS mutant Binimetinib lung adenocarcinoma decreased response detail...
KRAS G12V Selumetinib lung adenocarcinoma decreased response detail...
KRAS G12S Selumetinib lung adenocarcinoma decreased response detail...
KRAS G12C Selumetinib lung adenocarcinoma decreased response detail...
KRAS G12R Selumetinib lung adenocarcinoma decreased response detail...
KRAS G13C Selumetinib lung adenocarcinoma decreased response detail...
KRAS Q61K Selumetinib lung adenocarcinoma decreased response detail...
KRAS Q61H Selumetinib lung adenocarcinoma decreased response detail...
KRAS mutant Selumetinib lung adenocarcinoma decreased response detail...
FGFR1 positive AZD4547 + AZD8055 lung adenocarcinoma sensitive detail...
FGFR1 positive AZD4547 + Vistusertib lung adenocarcinoma sensitive detail...
FGFR1 positive AZD4547 + Sirolimus lung adenocarcinoma sensitive detail...
MET del exon14 Cabozantinib lung adenocarcinoma sensitive detail...
MET del exon14 Crizotinib lung adenocarcinoma sensitive detail...
BRAF G469L Vemurafenib lung adenocarcinoma no benefit detail...
MET over exp Merestinib lung adenocarcinoma sensitive detail...
MET over exp Telisotuzumab vedotin lung adenocarcinoma predicted - sensitive detail...
BRAF N581S PF3644022 + PF-477736 lung adenocarcinoma predicted - sensitive detail...
KRAS mutant PF3644022 + PF-477736 lung adenocarcinoma predicted - sensitive detail...
ERBB2 L869R Erlotinib lung adenocarcinoma resistant detail...
ERBB2 L869R Lapatinib lung adenocarcinoma resistant detail...
ERBB2 M774delinsWLV Dacomitinib lung adenocarcinoma sensitive detail...
ERBB2 G778_P780dup Dacomitinib lung adenocarcinoma sensitive detail...
KRAS G12D TP53 S127Y Dasatinib + Demcizumab lung adenocarcinoma sensitive detail...
KRAS G12R TP53 R248L Dasatinib + Demcizumab lung adenocarcinoma sensitive detail...
ATM del KRAS G12D Olaparib lung adenocarcinoma sensitive detail...
ATM del KRAS G12D VX-970 lung adenocarcinoma sensitive detail...
AKT1 E17K Capivasertib lung adenocarcinoma sensitive detail...
Unknown unknown Nintedanib + Docetaxel lung adenocarcinoma not applicable detail...
MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S Crizotinib lung adenocarcinoma resistant detail...
MET del exon14 Glesatinib lung adenocarcinoma sensitive detail...
MET amp MET del exon14 Crizotinib lung adenocarcinoma sensitive detail...
MET amp MET del exon14 MET D1228N MET G1163R MET L1195V Glesatinib lung adenocarcinoma resistant detail...
FGFR3 positive Rogaratinib lung adenocarcinoma predicted - sensitive detail...
BRAF G469A PLX8394 lung adenocarcinoma sensitive detail...
BRAF G466V PLX8394 lung adenocarcinoma sensitive detail...
BRAF amp BRAF V600E SCH772984 lung adenocarcinoma decreased response detail...
BRAF amp BRAF V600E Dabrafenib + SCH772984 + Trametinib lung adenocarcinoma sensitive detail...
ALK G1123S ALK rearrange Ceritinib lung adenocarcinoma predicted - resistant detail...
ALK G1123S ALK rearrange Alectinib lung adenocarcinoma predicted - sensitive detail...
EML4-ALK ALK C1156Y ALK L1196M Crizotinib lung adenocarcinoma resistant detail...
FGFR1 amp PRN1371 lung adenocarcinoma sensitive detail...
Unknown unknown AC-93253 iodide + Gefitinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange MET amp Alectinib lung adenocarcinoma resistant detail...
ALK rearrange MET amp Crizotinib lung adenocarcinoma sensitive detail...
KRAS mut STK11 mut unspecified PD-1 antibody lung adenocarcinoma predicted - resistant detail...
KRAS mutant TP53 mutant unspecified PD-1 antibody lung adenocarcinoma predicted - sensitive detail...
KRAS mutant unspecified PD-1 antibody lung adenocarcinoma predicted - sensitive detail...
Unknown unknown JNJ-64041757 lung adenocarcinoma not applicable detail...
KRAS G12S Afatinib lung adenocarcinoma sensitive detail...
KRAS G12S Erlotinib lung adenocarcinoma no benefit detail...
KRAS G12S Gefitinib lung adenocarcinoma no benefit detail...
KRAS G12C Afatinib lung adenocarcinoma sensitive detail...
RET M918T RET V804M Alectinib lung adenocarcinoma resistant detail...
BRAF V600E NRAS Q61K Trametinib + Dabrafenib lung adenocarcinoma predicted - resistant detail...
ERBB2 exon 20 ins Dacomitinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 amp Dacomitinib lung adenocarcinoma no benefit detail...
ERBB2 G776delinsVC Poziotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Poziotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 E812K Poziotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 N813D Afatinib lung adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01579994 Phase I Ganetespib + Crizotinib Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers Active, not recruiting
NCT01737502 Phase II Auranofin + Sirolimus PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer Recruiting
NCT01814553 Phase III Afatinib + Loperamide ADAM-Afatinib Diarrhea Assessment and Management Completed
NCT01877083 Phase II Lenvatinib Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Completed
NCT01877811 Phase Ib/II CEP-32496 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Active, not recruiting
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Active, not recruiting
NCT02185690 Phase I MEK162 + Carboplatin + Pemetrexed A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung Recruiting
NCT02231164 Phase III Docetaxel Nintedanib LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research Terminated
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + MEDI4736 AZD6738 + Olaparib Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting
NCT02285855 Phase II Metformin Metformin in Non Small Cell Lung Cancer (NSCLC) Terminated
NCT02450175 Phase I Letrozole Everolimus Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls Unknown status
NCT02450591 Phase I Erlotinib Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations Completed
NCT02466568 Phase Ib/II Nivolumab Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Withdrawn
NCT02513667 Phase II Ceritinib Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma Recruiting
NCT02705339 Phase II CO1686 Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) Withdrawn
NCT02759835 Phase II Osimertinib Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Recruiting
NCT02839681 Phase II Anetumab ravtansine Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma Terminated
NCT02864992 Phase II Tepotinib Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations Recruiting
NCT03076164 Phase Ib/II Erlotinib + Trametinib A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Recruiting
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Recruiting
NCT03371381 Phase Ib/II JNJ-64041757 + Nivolumab Nivolumab An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung Terminated
NCT03696212 Phase Ib/II Grapiprant + Pembrolizumab Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma Recruiting
NCT03704688 Phase Ib/II Ponatinib + Trametinib Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Recruiting